ATXS Key Statistics, Chart & Performance
The current stock price of ATXS is 12.64 USD. In the past month the price increased by 1.2%. In the past year, price increased by 32.22%.
ATXS Latest News, Press Relases and Analysis
ATXS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.44B | ||
| AMGN | AMGEN INC | 14.91 | 175.55B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.89 | 114.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.66 | 78.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 768.82 | 51.80B | ||
| INSM | INSMED INC | N/A | 42.33B | ||
| NTRA | NATERA INC | N/A | 31.12B | ||
| BIIB | BIOGEN INC | 10.28 | 25.25B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.36 | 22.00B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B | ||
| INCY | INCYTE CORP | 15.21 | 19.17B |
Related stock screener links
About ATXS
Company Profile
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2015-06-25. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. The company owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
Company Info
ASTRIA THERAPEUTICS INC
22 Boston Wharf Road, 10th Floor
Boston MASSACHUSETTS US
CEO: Jill C. Milne
Employees: 78
Phone: 16173491971
ASTRIA THERAPEUTICS INC / ATXS FAQ
Can you describe the business of ASTRIA THERAPEUTICS INC?
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2015-06-25. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. The company owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
What is the stock price of ASTRIA THERAPEUTICS INC today?
The current stock price of ATXS is 12.64 USD. The price decreased by -1.79% in the last trading session.
Does ATXS stock pay dividends?
ATXS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATXS stock?
ATXS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists ATXS stock?
ATXS stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of ASTRIA THERAPEUTICS INC (ATXS)?
ASTRIA THERAPEUTICS INC (ATXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
Would investing in ASTRIA THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ATXS.
ATXS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ATXS. When comparing the yearly performance of all stocks, ATXS is one of the better performing stocks in the market, outperforming 94.29% of all stocks.
ATXS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ATXS. While ATXS has a great health rating, there are worries on its profitability.
ATXS Financial Highlights
Over the last trailing twelve months ATXS reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 12.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.62% | ||
| ROE | -53.17% | ||
| Debt/Equity | 0 |
ATXS Forecast & Estimates
14 analysts have analysed ATXS and the average price target is 21.62 USD. This implies a price increase of 71.08% is expected in the next year compared to the current price of 12.64.